Patents Assigned to ABELZETA INC.
  • Publication number: 20250135000
    Abstract: The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA. The CAR may comprise an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.
    Type: Application
    Filed: December 27, 2024
    Publication date: May 1, 2025
    Applicant: ABELZETA INC.
    Inventors: Yihong YAO, Jiaqi HUANG, Shigui ZHU, Xin YAO, Xiaobing LUO, Yutian WEI
  • Publication number: 20250136707
    Abstract: The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA. The CAR may comprise an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.
    Type: Application
    Filed: December 31, 2024
    Publication date: May 1, 2025
    Applicant: ABELZETA INC.
    Inventors: Yihong YAO, Jiaqi HUANG, Shigui ZHU, Xin YAO, Xiaobing LUO, Yutian WEI
  • Publication number: 20250127815
    Abstract: The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA. The CAR may comprise an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.
    Type: Application
    Filed: December 30, 2024
    Publication date: April 24, 2025
    Applicant: ABELZETA INC.
    Inventors: Yihong YAO, Jiaqi HUANG, Shigui ZHU, Xin YAO, Xiaobing LUO, Yutian WEI
  • Publication number: 20240352417
    Abstract: Disclosed are a device and method for fully enclosed and fully automatic dispensing of cells. The device includes a sample feeding module, a liquid replenishment module, and a liquid distribution module. By means of the device, cell dispensing can be performed under enclosed conditions, such that the risk of infection due to contact with an external environment is reduced. In addition, the survival rate of dispensed cells is ensured, and the degree of precision of cells obtained after dispensing is high, thereby improving the quality of the dispensed cells.
    Type: Application
    Filed: August 24, 2022
    Publication date: October 24, 2024
    Applicant: AbelZeta Inc.
    Inventors: Fei WANG, Li XIE, Li ZHANG, Jiaqiang REN, Dijun ZHAO, Luyi ZHANG, Yiwen ZHOU
  • Publication number: 20240309337
    Abstract: Provided is a method for large-scale preparation of a purified preparation of a recombinant lentiviral vector at the GMP grade. The method comprises: (a) providing raw material feed liquid to be purified that comprises recombinant viral vectors; (b) carrying out a microfiltration treatment on the feed liquid to obtain a microfiltered filtrate comprising the recombinant viral vectors; (c) optionally concentrating the filtrate to obtain a concentrated filtrate; (d) purifying the filtrate obtained in the previous step by means of chromatography to obtain a crude pure product comprising the recombinant viral vectors; and (e) subjecting the crude pure product obtained in the previous step to liquid exchange and elaborate purification to obtain the purified recombinant viral vectors.
    Type: Application
    Filed: May 24, 2024
    Publication date: September 19, 2024
    Applicant: ABELZETA INC.
    Inventors: Yi HONG, Ting YAN, Jiangguo YING, Haojie ZHANG, Li ZHANG, Fei WANG, Dijun ZHAO, Luyi ZHANG
  • Patent number: 12018293
    Abstract: Provided is a method for large-scale preparation of a purified preparation of a recombinant lentiviral vector at the GMP grade. The method comprises: (a) providing raw material feed liquid to be purified that comprises recombinant viral vectors; (b) carrying out a microfiltration treatment on the feed liquid to obtain a microfiltered filtrate comprising the recombinant viral vectors; (c) optionally concentrating the filtrate to obtain a concentrated filtrate; (d) purifying the filtrate obtained in the previous step by means of chromatography to obtain a crude pure product comprising the recombinant viral vectors; and (e) subjecting the crude pure product obtained in the previous step to liquid exchange and elaborate purification to obtain the purified recombinant viral vectors.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: June 25, 2024
    Assignee: ABELZETA INC.
    Inventors: Yi Hong, Ting Yan, Jiangguo Ying, Haojie Zhang, Li Zhang, Fei Wang, Dijun Zhao, Luyi Zhang